Acute Severe Animal Model of Anti–Muscle-Specific Kinase Myasthenia

Authors:

Abstract
Ninety percent of patients with generalized myasthenia gravis (MG) have pathogenic antibodies (Abs) to the nicotinic acetylcholine receptor (AChR), the neuromuscular junction (NMJ) postsynaptic neurotransmitter receptor. However, in about 5% of cases, AChR Abs are absent but the patients have circulating Abs to a second postsynaptic NMJ protein, muscle-specific kinase (MuSK).1 These patients, which we will refer to as having anti-MuSK myasthenia (AMM), have many clinical similarities to those with AChR Ab–positive MG but tend to differ significantly in having more focal involvement with severe weakness of neck, shoulder, facial, and bulbar muscles, frequently with wasting of these muscles.2-5 In contrast to AChR Ab–positive MG, the pathogenic mechanisms underlying AMM are not well understood. In fact, there has been debate over whether MuSK Abs play a direct role in AMM or simply represent an epiphenomenon.6,7 Our study is aimed at addressing this question and better defining the mechanisms by which such an immune attack may produce the disease.

This publication has 43 references indexed in Scilit: